Maximum Lorazepam Dose in 24 Hours
The FDA-approved maximum dose of lorazepam (Ativan) is 10 mg per day for oral administration, though the injectable formulation does not specify an absolute maximum daily dose—instead emphasizing that doses above 4 mg IV/IM carry increased risks of excessive sedation, prolonged effects, and propylene glycol toxicity. 1
FDA-Approved Dosing Parameters
Injectable Lorazepam (IV/IM)
- Standard preoperative dose: 2-4 mg IV/IM 1
- Doses above 4 mg: Associated with excessive sleepiness, prolonged lack of recall, and effects lasting >24 hours 1
- Doses of 8-10 mg IV: Produce loss of lid reflexes within 15 minutes and represent 2 to 2.5 times the maximum recommended dosage 1
Critical Propylene Glycol Toxicity Risk
Total daily IV doses as low as 1 mg/kg can cause propylene glycol toxicity, manifesting as metabolic acidosis and acute kidney injury 2. The parenteral formulation contains propylene glycol as a diluent, and while initially thought to accumulate only at very high continuous infusion rates (15-25 mg/hr), current evidence demonstrates toxicity at much lower cumulative doses 2. An osmol gap >10-12 mOsm/L should trigger suspicion for propylene glycol accumulation 2.
ICU Sedation Context
For continuous infusion in mechanically ventilated patients, current guidelines strongly recommend against benzodiazepines as first-line sedation due to worse outcomes compared to propofol or dexmedetomidine 3. When lorazepam was used historically in ICU trials, typical dosing ranged from 2-4 mg/hour continuous infusion, but this practice has fallen out of favor 3.
Research data show:
- Continuous infusion at 2 mcg/kg/hr (approximately 0.14 mg/kg/hr for a 70 kg patient = ~10 mg/hr) maintained steady-state concentrations without tolerance over 4 hours 4
- ICU patients historically received up to 4 mg every 4-6 hours (16-24 mg/day) for periods up to 25 days, though this predates modern safety data 5
Practical Dosing Algorithm
For acute/intermittent use:
- Start with 2 mg IV/IM for preoperative sedation
- Maximum single dose: 4 mg
- Avoid exceeding 8-10 mg total in 24 hours unless absolutely necessary
- Monitor osmol gap if cumulative dose approaches 1 mg/kg (70 mg in a 70 kg patient)
For continuous sedation (not recommended as first-line):
- Consider alternative agents (propofol, dexmedetomidine) first 3, 2
- If lorazepam used, monitor for propylene glycol toxicity at any dose
- Elderly patients require dose reduction due to 50% higher volume of distribution and 2-fold longer half-life 1
Critical Safety Considerations
- Respiratory depression: Especially when combined with opioids—monitor closely 1
- Prolonged effects: Visual tracking impaired for mean of 8 hours after 4 mg IM; enhanced alcohol sensitivity persists >24 hours 1
- Age-related differences: Patients >50 years have higher incidence of excessive sedation (21/106 vs 24/245 in younger patients) 1
- Neonates: 80% reduced clearance and 3-fold prolonged half-life compared to adults 1
The absence of a specific maximum daily dose in the FDA label for injectable lorazepam reflects the context-dependent nature of dosing, but the propylene glycol toxicity threshold of 1 mg/kg/day (approximately 70 mg for a 70 kg adult) represents a practical upper safety limit 2.